908 Devices, a Boston, MA-based developer of purpose-built analytical devices for chemical analysis, raised an additional growth equity investment as a part of Series C funding round.
Backers included Casdin Capital, Dr. Martin Madaus, Chairman and CEO of Ortho Clinical Diagnostics; Paul Meister, former Chairman of the Board of Thermo Fisher Scientific Inc., and others.
The company, which has now raised $29m, intends to use the funds to accelerate growth into the life sciences market.
Led by Dr. Kevin J. Knopp, President and CEO, 908 Devices is an innovator in point-of-need chemical analysis. It offers products from rugged, handheld chemical detection tools to compact, tiny footprint analyzers for researchers, serving a range of industries including safety and security, energy, petrochemical, and life sciences.